Cargando…

Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara

BACKGROUND: This study aimed at describing the type and dosage of psychopharmaceuticals dispensed to patients with psychiatric disorders and to assess the percentage of patients treated with antipsychotics and antidepressants, the associated therapies, treatment adherence, and dosages used in indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Stefano, Bianchini, Erica, Scanavacca, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293025/
https://www.ncbi.nlm.nih.gov/pubmed/22185397
http://dx.doi.org/10.1186/1472-6904-11-21
_version_ 1782225354860003328
author Bianchi, Stefano
Bianchini, Erica
Scanavacca, Paola
author_facet Bianchi, Stefano
Bianchini, Erica
Scanavacca, Paola
author_sort Bianchi, Stefano
collection PubMed
description BACKGROUND: This study aimed at describing the type and dosage of psychopharmaceuticals dispensed to patients with psychiatric disorders and to assess the percentage of patients treated with antipsychotics and antidepressants, the associated therapies, treatment adherence, and dosages used in individuals registered at the Psychiatric Disease Center (PDC), Regional Health Service of Ferrara. METHODS: The analysis focused on therapeutic programmes presented to the Department of Pharmacy of the University Hospital of Ferrara of 892 patients treated by the PDC (catchment area of 134605 inhabitants). All diagnoses were made according to International Classification of Diseases (ICD-9). The analysis focused on prescriptions from September 2007 to June 2009. Data on adherence to prescribed therapy have were processed by analysis of variance. RESULTS: Among the patients 63% were treated with antipsychotics and 40% with antidepressants. Among patients receiving antipsychotics 92% used second-generation antipsychotics (SGAs) whereas the remaining 8% used first generation antipsychotics (FGAs). Antipsychotic doses were lower than Daily Defined Dose (DDDs), and SGAs were often given with anticholinergics to decrease side effects. Mean adherence to antipsychotic therapy was 64%. Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) were the most often prescribed, 55%. Dosages of these were within the limits indicated by the technical datasheet but higher than DDDs. Only 26% of patients underwent monotherapy. In antidepressants polytherapy, medication was associated with another antidepressant, 6% or with an antipsychotic, 51%. Mean adherence to the antidepressant therapy was 64%. CONCLUSIONS: Patients treated with antipsychotics tend to use doses lower than DDDs. The opposite tendency was noted in patients treated with antidepressants. Only a small percentage of patients (14%) modified their neuroleptic therapy by increasing the dosage. On the contrary, patients treated with antidepressants mainly tended to reduce the doses of their drugs. This study highlights the tendency to follow combination therapies, prescribing SGAs together with anticholinergics in order to minimize extrapyramidal side effects or by combining two antidepressants. The study showed low adherence for both pharmaceutical therapies, which is typical in the setting of the analyzed diseases.
format Online
Article
Text
id pubmed-3293025
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32930252012-03-05 Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara Bianchi, Stefano Bianchini, Erica Scanavacca, Paola BMC Clin Pharmacol Research Article BACKGROUND: This study aimed at describing the type and dosage of psychopharmaceuticals dispensed to patients with psychiatric disorders and to assess the percentage of patients treated with antipsychotics and antidepressants, the associated therapies, treatment adherence, and dosages used in individuals registered at the Psychiatric Disease Center (PDC), Regional Health Service of Ferrara. METHODS: The analysis focused on therapeutic programmes presented to the Department of Pharmacy of the University Hospital of Ferrara of 892 patients treated by the PDC (catchment area of 134605 inhabitants). All diagnoses were made according to International Classification of Diseases (ICD-9). The analysis focused on prescriptions from September 2007 to June 2009. Data on adherence to prescribed therapy have were processed by analysis of variance. RESULTS: Among the patients 63% were treated with antipsychotics and 40% with antidepressants. Among patients receiving antipsychotics 92% used second-generation antipsychotics (SGAs) whereas the remaining 8% used first generation antipsychotics (FGAs). Antipsychotic doses were lower than Daily Defined Dose (DDDs), and SGAs were often given with anticholinergics to decrease side effects. Mean adherence to antipsychotic therapy was 64%. Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) were the most often prescribed, 55%. Dosages of these were within the limits indicated by the technical datasheet but higher than DDDs. Only 26% of patients underwent monotherapy. In antidepressants polytherapy, medication was associated with another antidepressant, 6% or with an antipsychotic, 51%. Mean adherence to the antidepressant therapy was 64%. CONCLUSIONS: Patients treated with antipsychotics tend to use doses lower than DDDs. The opposite tendency was noted in patients treated with antidepressants. Only a small percentage of patients (14%) modified their neuroleptic therapy by increasing the dosage. On the contrary, patients treated with antidepressants mainly tended to reduce the doses of their drugs. This study highlights the tendency to follow combination therapies, prescribing SGAs together with anticholinergics in order to minimize extrapyramidal side effects or by combining two antidepressants. The study showed low adherence for both pharmaceutical therapies, which is typical in the setting of the analyzed diseases. BioMed Central 2011-12-20 /pmc/articles/PMC3293025/ /pubmed/22185397 http://dx.doi.org/10.1186/1472-6904-11-21 Text en Copyright ©2011 Bianchi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bianchi, Stefano
Bianchini, Erica
Scanavacca, Paola
Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title_full Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title_fullStr Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title_full_unstemmed Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title_short Use of antipsychotic and antidepressant within the Psychiatric Disease Centre, Regional Health Service of Ferrara
title_sort use of antipsychotic and antidepressant within the psychiatric disease centre, regional health service of ferrara
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293025/
https://www.ncbi.nlm.nih.gov/pubmed/22185397
http://dx.doi.org/10.1186/1472-6904-11-21
work_keys_str_mv AT bianchistefano useofantipsychoticandantidepressantwithinthepsychiatricdiseasecentreregionalhealthserviceofferrara
AT bianchinierica useofantipsychoticandantidepressantwithinthepsychiatricdiseasecentreregionalhealthserviceofferrara
AT scanavaccapaola useofantipsychoticandantidepressantwithinthepsychiatricdiseasecentreregionalhealthserviceofferrara